Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Directorate Change

10 May 2016 07:00

RNS Number : 7154X
CATCo Reinsurance Opps Fund Ltd
10 May 2016
 

 

CATCo Reinsurance Opportunities Fund Ltd (the "Company").

Executive changes at Markel CATCo Investment Management Ltd.

 

To: SFM, London Stock Exchange and 10 May 2016

Bermuda Stock Exchange

 

The Company announces the following executive change at its Manager, Markel CATCo Investment Management Ltd. ("Markel CATCo").

 

In line with its planned strategy, Markel CATCo intends to appoint Lindsay Watson as Chief Underwriting Officer. As part of this process, and by mutual agreement, Graham Wood, Chief Underwriting Officer, has today stepped down from Markel CATCo.

Lindsay, who is currently Senior Underwriter at Markel CATCo, has over 13 years' experience in the US, Bermuda and London Property and Casualty reinsurance markets.

Prior to joining Markel CATCo, Lindsay was a senior underwriter at Amlin (now MS Amlin), one of the world's largest reinsurance companies. Prior to this, she worked for the reinsurance broker Guy Carpenter. Lindsay is a qualified Associate in Reinsurance.

Graham Wood was one of the founding directors of CATCo Investment Management Ltd. which was acquired by Markel Corporation on 8 December 2015. He has been part of the senior management team which has seen Markel CATCo's AUM grow to over $3bn.

Tony Belisle, Chief Executive Officer of Markel CATCo Investment Management Ltd., said:

"Graham's close management of our client relationships has been immense and I am very grateful for all of his help in building the business to the size it now is. We wish him well on his return to the UK.

"Lindsay has all of the necessary underwriting skills to move the business forward during this next stage of Markel CATCo's development. Lindsay is already fully immersed in all of the reinsurance business conducted at Markel CATCo and she was brought in originally as part of the underwriting team succession plan."

 

For further information:

Judith Wynne

General Counsel

Markel CATCo Investment Management Ltd.

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief Operating Officer

Markel CATCo Investment Management Ltd.

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

 

David Benda / Hugh Jonathan

Numis Securities Limited

Telephone: +44 (0) 20 7260 1000

 

 

- ends -

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUGUBWAUPQPUB
Date   Source Headline
13th Jun 20064:50 pmRNSRule 8.3- Cambridge Antibody
13th Jun 20063:54 pmRNSRule 2.10 Announcement
13th Jun 200612:18 pmRNSEPT Disclosure
13th Jun 200611:42 amRNSEPT Disclosure
13th Jun 200611:35 amRNSEPT Disclosure
13th Jun 200610:20 amRNSEPT Disclosure
12th Jun 20065:35 pmRNSRule 8.3 - Cambridge Antibody
12th Jun 200612:00 pmRNSEPT Disclosure
12th Jun 200611:34 amRNSEPT Disclosure
12th Jun 200611:14 amRNSRule 8.3- (CAT)
12th Jun 200610:08 amRNSEPT Disclosure
12th Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
9th Jun 20061:30 pmRNSRule 8.3- (CAT)
9th Jun 200612:36 pmRNSEPT Disclosure
9th Jun 200611:56 amRNSEPT Disclosure
9th Jun 200611:54 amRNSEPT Disclosure
9th Jun 200611:38 amRNSRule 8.3-Cambridge Antibody
8th Jun 20064:19 pmRNSRule 2.10 Announcement
8th Jun 20062:21 pmRNSEPT Disclosure
8th Jun 20061:14 pmRNSRule 8.3- (CAT)
8th Jun 200610:49 amRNSEPT Disclosure
7th Jun 20065:01 pmRNSHolding(s) in Company
7th Jun 20064:55 pmRNSRule 8.3- Cambridge Anti Tech
7th Jun 200612:38 pmRNSRule 8.3- (CAT)
7th Jun 200612:08 pmRNSEPT Disclosure
7th Jun 200610:00 amRNSOffer for Cambridge Antibody
6th Jun 20064:01 pmRNSRule 8.3- Cambridge Antibody
6th Jun 20063:45 pmRNSRule 8.3- Cambridge Antibody
6th Jun 200612:43 pmRNSEPT Disclosure
5th Jun 20066:00 pmRNSEPT Disclosure
5th Jun 20061:10 pmRNSRule 8.3- (CAT)
5th Jun 200612:55 pmRNSEPT Disclosure
5th Jun 200611:24 amRNSEPT Disclosure
2nd Jun 20062:14 pmRNSEPT Disclosure
2nd Jun 20061:19 pmRNSRule 8.3- (CAT)
2nd Jun 200612:27 pmRNSEPT Disclosure
2nd Jun 200612:22 pmRNSEPT Disclosure
2nd Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
1st Jun 20064:22 pmRNSRule 8.3- Cambridge Antibody
1st Jun 20063:21 pmRNSHolding(s) in Company
1st Jun 200612:25 pmRNSEPT Disclosure
1st Jun 200611:10 amRNSEPT Disclosure
31st May 20063:13 pmRNSRule 8.3- (CAT)
31st May 20063:00 pmRNSMerger Update
31st May 20061:04 pmRNSRule 8.3- Cambridge Antibody
31st May 200611:43 amRNSEPT Disclosure
31st May 200611:27 amRNSEPT Disclosure
31st May 200611:25 amRNSEPT Disclosure
30th May 20063:25 pmRNSRule 8.3- (CAT)
30th May 20063:16 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.